Mauricio Dídac
Servicio de Endocrinología y Nutrición, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.
Med Clin (Barc). 2013 Sep;141 Suppl 2:31-5. doi: 10.1016/S0025-7753(13)70061-7.
The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. We are currently witnessing the introduction of a new mode of hypoglycemic treatment through induction of glycosuria to decrease the availability of the metabolic substrate, i.e. glucose. Clinical trials have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitors are as efficacious as other oral hypoglycemic drugs. This article discusses the basic features of this new treatment concept and the efficacy and safety of this new drug group.
2型糖尿病高血糖治疗的治疗手段仍然不足。我们目前正在见证一种通过诱导糖尿以减少代谢底物即葡萄糖的可用性来进行降血糖治疗的新模式的引入。临床试验表明,钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与其他口服降糖药一样有效。本文讨论了这一新治疗理念的基本特征以及这一新药组的疗效和安全性。